MDT

84.83

+1.33%↑

VEEV

231.93

+3.06%↑

A

107.72

+1.87%↑

WBA

10.97

+0.09%↑

CHE

581.87

+4%↑

MDT

84.83

+1.33%↑

VEEV

231.93

+3.06%↑

A

107.72

+1.87%↑

WBA

10.97

+0.09%↑

CHE

581.87

+4%↑

MDT

84.83

+1.33%↑

VEEV

231.93

+3.06%↑

A

107.72

+1.87%↑

WBA

10.97

+0.09%↑

CHE

581.87

+4%↑

MDT

84.83

+1.33%↑

VEEV

231.93

+3.06%↑

A

107.72

+1.87%↑

WBA

10.97

+0.09%↑

CHE

581.87

+4%↑

MDT

84.83

+1.33%↑

VEEV

231.93

+3.06%↑

A

107.72

+1.87%↑

WBA

10.97

+0.09%↑

CHE

581.87

+4%↑

Search

Omeros Corp

Open

SectorGezondheidszorg

7.42 2.49

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.05

Max

7.46

Belangrijke statistieken

By Trading Economics

Inkomsten

874K

-31M

EPS

-0.541

Werknemers

202

EBITDA

-239K

-33M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+254.88% upside

Dividenden

By Dow Jones

Volgende Winsten

14 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-102M

389M

Vorige openingsprijs

4.93

Vorige sluitingsprijs

7.42

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Omeros Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 apr 2025, 23:27 UTC

Top Nieuws

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28 apr 2025, 23:07 UTC

Top Nieuws

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28 apr 2025, 23:03 UTC

Winsten

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28 apr 2025, 23:47 UTC

Marktinformatie

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28 apr 2025, 23:17 UTC

Winsten

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28 apr 2025, 23:17 UTC

Winsten

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28 apr 2025, 23:13 UTC

Winsten

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28 apr 2025, 23:13 UTC

Winsten

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28 apr 2025, 23:13 UTC

Winsten

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28 apr 2025, 23:13 UTC

Winsten

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28 apr 2025, 23:08 UTC

Winsten

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28 apr 2025, 23:08 UTC

Winsten

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28 apr 2025, 23:08 UTC

Winsten

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28 apr 2025, 23:04 UTC

Winsten

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28 apr 2025, 23:04 UTC

Winsten

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28 apr 2025, 23:04 UTC

Winsten

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28 apr 2025, 23:04 UTC

Winsten

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28 apr 2025, 23:00 UTC

Winsten

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28 apr 2025, 23:00 UTC

Winsten

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28 apr 2025, 23:00 UTC

Winsten

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28 apr 2025, 23:00 UTC

Winsten

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28 apr 2025, 22:57 UTC

Top Nieuws

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28 apr 2025, 22:55 UTC

Winsten

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28 apr 2025, 22:55 UTC

Winsten

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28 apr 2025, 22:55 UTC

Winsten

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28 apr 2025, 22:52 UTC

Winsten

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28 apr 2025, 22:52 UTC

Winsten

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28 apr 2025, 22:52 UTC

Winsten

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28 apr 2025, 22:52 UTC

Winsten

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28 apr 2025, 22:46 UTC

Winsten

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Peer Vergelijking

Prijswijziging

Omeros Corp Prognose

Koersdoel

By TipRanks

254.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25.8 USD  254.88%

Hoogste 45 USD

Laagste 6.608 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Omeros Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technische score

By Trading Central

6.7901 / 7.3Steun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.